Design and synthesis of long-acting inhibitors of dipeptidyl peptidase IV

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 7, 2007, Pages 2715-2735

  Kondo, Takashi ^a   Sugimoto, Isamu ^a   Nekado, Takahiro ^a   Ochi, Kenya ^a   Ohtani, Tazumi ^a   Tajima, Yohei ^a   Yamamoto, Susumu ^a   Kawabata, Kazuhito ^a   Nakai, Hisao ^a   Toda, Masaaki ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

DPP IV inhibitor; Glucuronate; Prolylprolinenitriles

Indexed keywords

1 [(4 ALLYL 2 PYRROLIDINYL)CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [(4 CYCLOHEXYL 2 PYRROLIDINYL)CARBONYL] 2 PYRROLIDINECARBONITRILE; 1 [(4 ISOBUTYL 2 PYRROLIDINYL)CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [(4 PHENYL 2 PYRROLIDINYL)CARBONYL] 2 PYRROLIDINECARBONITRILE; 1 [(4 PHENYL 2 PYRROLIDINYL)CARBONYL] 2 PYRROLIDINECARBONITRILE BENZENESULFONATE; 1 [(4 PROPYL 2 PYRROLIDINYL)CARBONYL] 2 PYRROLIDINECARBONITRILE; 1 [[(2 ETHYL 4 HYDROXY 6 METHYLPHENYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[(2 METHYL 2 PROPEN 1 YL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[(2,6 DIETHOXY 4 HYDROXYPHENYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (2 ADAMANTYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (2 HYDROXYPHENYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (2,6 DIMETHYLPHENYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE; 1 [[4 (3 HYDROXY 2 METHOXY 6 METHYLPHENYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (3 HYDROXY 2,4,6 TRIMETHYLPHENYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (3 HYDROXY 2,6 DIMETHYLPHENYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (3 HYDROXYPHENYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (4 HYDROXY 2 METHOXY 6 METHYLPHENYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE; 1 [[4 (4 HYDROXY 2,6 DIMETHOXYPHENYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (4 HYDROXY 2,6 DIMETHYLPHENYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; 1 [[4 (4 HYDROXYPHENYL) 2 PYRROLIDINYL]CARBONYL] 2 PYRROLIDINECARBONITRILE 4 METHYLBENZENESULFONATE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCURONIC ACID; LONG ACTING DRUG; PHENOL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; ENZYME INHIBITION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIGENS, CD26; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, THIN LAYER; DRUG DESIGN; DRUG STABILITY; GLUCURONIDASE; HUMANS; INDICATORS AND REAGENTS; MALE; MICROSOMES, LIVER; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SOLUTIONS; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847650981     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.01.033     Document Type: Article

References (53)

1. King H., Aubert R.E., and Herman W.H. Diabetes Care 21 (1998) 1414
2. Wagman A.S., and Nuss J.M. Curr. Pharm. Des. 7 (2001) 417
3. Harris M.I., Hadden W.C., Knowler W.C., and Bennet P.H. Diabetes 36 (1987) 523
4. Saltiel A.R., and Olefsky J.M. Diabetes 45 (1996) 1661
5. Schoonjans K., Martin G., Staels B., and Auwerx J. Curr. Opin. Lipidol. 8 (1997) 159
6. Pittas A.G., and Greenberg A.S. Expert Opin. Pharmacother. 3 (2002) 529
7. Rami H.K., and Smith S.A. Expert Opin. Ther. Pat. 10 (2000) 623
8. Van Gaal L., and Scheen A.J. Diabetes Metab. Res. Rev. 18 (2002) S1-S4
9. Hauner H. Diabetes Metab. Res. Rev. 18 (2002) S10-S15
10. Rosenstock J., Schwartz S.L., Clark Jr. C.M., Park G.D., Donley D.W., and Edwards M.B. Diabetes Care 24 (2001) 631
11. Barnett A.H., and Owens D.R. Lancet 349 (1997) 47
12. United Kingdom Prospective Diabetes Study Group Br. Med. J. 1995, 310, 83.
13. United Kingdom Prospective Diabetes Study Group Metabolism 1990, 39, 905.
14. Gerich J.E. N. Engl. J. Med. 321 (1989) 1231
15. Witters L. J. Clin. Invest. 108 (2001) 1105
16. Bailey C.J., Path M.R.C., and Turner R.C. N. Engl. J. Med. 334 (1996) 574
17. Lillelund V.H., Jensen H.H., Liang X., and Bols M. Chem. Rev. 102 (2002) 515
18. Berecibar A., Grandjean C., and Siriwardena. Chem. Rev. 99 (1999) 779
19. Jacob G.S. Curr. Opin. Struct. Biol. 5 (1995) 605
20. Holst J.J. Gastroenterology 107 (1994) 1048
21. Orsakov C. Diabetologia 35 (1992) 701
22. Drucker D.J. Diabetes 47 (1998) 159
23. Gutniak M., Orskov C., Holst J.J., Ahren B., and Efendic S. N. Engl. J. Med. 326 (1992) 1316
24. Nauck M.A., Kleine N., Orskov C., Holst J.J., Willms B., and Creutzfeldt W. Diabetologia 36 (1993) 741
25. Gutniak M.K., Linde B., Holst J.J., and Efendic S. Diabetes Care 17 (1994) 1039
26. Vilsbøll T., Krarup T., Madsbad S., and Holst J.J. Regul. Peptides 114 (2003) 115
27. Ogata S., Misumi Y., and Ikehara Y. J. Biol. Chem. 264 (1989) 3596
28. Ahre'n B., Simonsson E., Larsson H., Landin-Olsson M., Torgeirsson H., Jansson P.-A., Sandqvist M., Bavenholm P., Efendic S., Eriksson J.W., Dickinson S., and Holmes D. Diabetes Care 25 (2002) 869
29. Ahre'n B., Landin-Olsson M., Jansson P.-A., Eriksson J., Pacini G., Thomaseth K., and Schweizer A. Diabetes 52 (2003) A15
30. Ahre'n B., Gomis R., Standl E., Mills D., and Schweizer A. Diabetes Care 27 (2004) 2874
31. Weber A.E. J. Med. Chem. 47 (2004) 4135
32. Augustyns K., Van der Veken P., Senten K., and Haemers A. Exp. Opin. Ther. Pat. 13 (2003) 499
33. Wiedeman P.E., and Trevillyan J.M. Curr. Opin. Invest. Drugs 4 (2003) 412
34. Ashworth D.M., Atrash B., Baker G.R., Baxter A.J., Jenkins P.D., Jones D.M., and Szelke M. Biorg. Med. Chem. Lett. 6 (1996) 1163
35. Hughes T.E., Mone M.D., Russell M.E., Weldon S.C., and Villhauer E.B. Biochemistry 38 (1999) 11597
36. Villhauer E.B., Brinkman J.A., Naderi G.B., Dunning B.E., Mangold B.L., Mone M.D., Russell M.E., Weldon S.C., and Hughes T.E. J. Med. Chem. 45 (2002) 2362
37. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., Mangold B.L., Russell M.E., and Hughes T.E. J. Med. Chem. 46 (2003) 2774
38. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., Wang A., Simpkins L.M., Taunk P., Huang Q., Han S.P., Abboa-Offei B., Cap M., Xin L., Tao L., Tozzo E., Welzel G.E., Egan D.M., Marcinkeviciene J., Chang S.Y., Biller S.A., Kirby M.S., Parker R.A., and Hamann L.G. J. Med. Chem. 48 (2005) 5025
39. Sakashita H., Kitajima H., Nakamura M., Akahoshi F., and Hayashi Y. Biorg. Med. Chem. Lett. 15 (2005) 2441
40. Sakashita H., Akahoshi F., Kitajima H., Reiko Tsutsumiuchi R., and Hayashi Y. Biorg. Med. Chem. 14 (2006) 3662
41. Sakashita H., Akahoshi F., Yoshida T., Kitajima H., Hayashi Y., Ishii S., Takashina Y., Tsutsumiuchi R., and Ono S. Biorg. Med. Chem. 15 (2007) 641
42. Pei Z., Li X., Longenecker K., von Geldern T.W., Wiedeman P.E., Lubben T.H., Zinker B.A., Stewart K., Ballaron S.J., Stashko M.A., Mika A.K., Beno D.W.A., Long M., Wells H., Kempf-Grote A.J., Madar D.J., McDermott T.S., Bhagavatula L., Fickes M.G., Pireh D., Solomon L.R., Lake M.R., Edalji R., Fry E.H., Sham H.L., and Trevillyan J.M. J. Med. Chem. 49 (2006) 3520
43. Pei, Z.; Li, X.; Longenecker, K.; Sham, H. L.; Wiedeman, P. E. WO2005023762.
44. Bernard, H.; Walter, P. D. WO 2005116014.
45. Krapcho J., Turk C., Cushuman D.W., Powell J.R., DeForrest J.M., Spitzmiller E.R., Karanewsky D.S., Duggan M., Rovnvak G., Schwartz J., Natarajan S., Godfrey J.D., Ryono D.E., Neubeck R., Atwal K.S., and Petrillo Jr. E.W. J. Med. Chem. 31 (1988) 1148
46. Hanessian S., and Margarita R. Tetrahedron Lett. 39 (1998) 5887
47. Ezquerra J., Pedregal C., Yruretagoyena B., Rubio A., Carreño M.C., Escribano A., and Ruano J.L.G. J. Org. Chem. 60 (1995) 2925
48. Pedregal C., Ezquerra J., Escribano A., Carreño M.C., and Ruano J.L.G. Tetrahedron Lett. 35 (1994) 2053
49. Duke-Cohan J.S., Morimoto C., Rocker J.A., and Schlossman S.F. J. Biol. Chem. 270 (1995) 14107
50. Iwaki-Egawa S., Watanabe Y., Kikuya Y., and Fujimoto Y. J. Biochem. 124 (1998) 238
51. Masafumi K., Tohoru N., and Jiro K. J. Biochem. 97 (1985) 1211
52. Compounds 5 and 7 were stereoselectively synthesized according to the method reported in Ref. 18.
53. 3CN, linear gradient 5% to 80% of eluent B in eluent A in 25 min; flow rate: 1 mL/min). The fractions (retention time, 5-6 min), which showed inhibitory activity, were collected and analyzed by LC/MS/MS. The only metabolite detected was the one possessing m/z = 462, which corresponds to glucuronated phenolic metabolite of 11. The metabolite was treated with glucuronidase and then analyzed by HPLC under the same condition as described above. The resulting material (retention time, 11 min) was found to be identical with that of para-phenolic analog 16, which was not detected in the above-described experimental condition.